share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K：外国发行人报告
美股SEC公告 ·  10/24 07:34

Moomoo AI 已提取核心信息

NeuroSense Therapeutics Ltd., a biotechnology company, announced on October 24, 2024, significant findings from its PARADIGM clinical trial for PrimeC, a treatment for ALS (Amyotrophic Lateral Sclerosis). The trial results showed that PrimeC significantly regulates key microRNAs (miRNAs) involved in ALS progression, offering new hope for treating the disease. PrimeC, an extended-release oral formulation combining ciprofloxacin and celecoxib, targets multiple key mechanisms of ALS. The trial included 68 participants across Canada, Italy, and Israel, with 96% choosing to continue PrimeC treatment after the 6-month double-blind portion. The data indicated a 29% difference in efficacy in favor of PrimeC over placebo, with a 37.4% slowing of disease progression observed. PrimeC has been granted Orphan Drug Designation by the FDA and the European Medicines Agency. NeuroSense is dedicated to developing treatments that address the root causes of neurodegenerative diseases and believes PrimeC's ability to regulate miRNAs is a significant step toward providing more therapeutic options for ALS patients.
NeuroSense Therapeutics Ltd., a biotechnology company, announced on October 24, 2024, significant findings from its PARADIGM clinical trial for PrimeC, a treatment for ALS (Amyotrophic Lateral Sclerosis). The trial results showed that PrimeC significantly regulates key microRNAs (miRNAs) involved in ALS progression, offering new hope for treating the disease. PrimeC, an extended-release oral formulation combining ciprofloxacin and celecoxib, targets multiple key mechanisms of ALS. The trial included 68 participants across Canada, Italy, and Israel, with 96% choosing to continue PrimeC treatment after the 6-month double-blind portion. The data indicated a 29% difference in efficacy in favor of PrimeC over placebo, with a 37.4% slowing of disease progression observed. PrimeC has been granted Orphan Drug Designation by the FDA and the European Medicines Agency. NeuroSense is dedicated to developing treatments that address the root causes of neurodegenerative diseases and believes PrimeC's ability to regulate miRNAs is a significant step toward providing more therapeutic options for ALS patients.
NeuroSense Therapeutics Ltd.，一家生物技术公司，于2024年10月24日宣布，其PARADIGm临床试验为ALS（肌萎缩侧索硬化症）的治疗PrimeC取得重要发现。试验结果显示，PrimeC显著调节与ALS进展有关的关键miRNA（microRNA），为治疗该疾病带来新希望。PrimeC是一种延时释放口服制剂，结合了环丙沙星和塞来昔布，针对ALS的多种关键机制。该试验包括加拿大、意大利和以色列的68名参与者，其中96%选择在6个月的双盲阶段后继续PrimeC治疗。数据显示，PrimeC比安慰剂的有效性差异为29％，疾病进展减缓了37.4％。PrimeC已获得FDA和欧洲药品管理局的孤儿药物认定。NeuroSense致力于研发治疗神经退行性疾病根本原因的药物，并认为PrimeC调节miRNA的能力是向ALS患者提供更多治疗选择的重要一步。
NeuroSense Therapeutics Ltd.，一家生物技术公司，于2024年10月24日宣布，其PARADIGm临床试验为ALS（肌萎缩侧索硬化症）的治疗PrimeC取得重要发现。试验结果显示，PrimeC显著调节与ALS进展有关的关键miRNA（microRNA），为治疗该疾病带来新希望。PrimeC是一种延时释放口服制剂，结合了环丙沙星和塞来昔布，针对ALS的多种关键机制。该试验包括加拿大、意大利和以色列的68名参与者，其中96%选择在6个月的双盲阶段后继续PrimeC治疗。数据显示，PrimeC比安慰剂的有效性差异为29％，疾病进展减缓了37.4％。PrimeC已获得FDA和欧洲药品管理局的孤儿药物认定。NeuroSense致力于研发治疗神经退行性疾病根本原因的药物，并认为PrimeC调节miRNA的能力是向ALS患者提供更多治疗选择的重要一步。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间